← Aprea Therapeutics, Inc. (APRE) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Aprea Therapeutics, Inc. (APRE)
Pharmaceutical Preparations · market cap $10M · as of 2026-10-11
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-11 (est.)
Earnings
Pipeline
6
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Aprea Therapeutics (APRE) is a micro-cap oncology company with 8 employees, a ~$8M market cap and a ~$0.6 share price on ~12.6M shares. Our database lists a broad pipeline led by APR-246 + azacitidine (Phase 3, MDS), plus Phase 2 programs in ovarian cancer, AML/MDS and advanced solid tumors. The setup is dominated by a balance-sheet anomaly: reported cash of $41.2M is roughly 5x the market cap.
The catalyst path
- 2026-11-11 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| APR-246 + azacitidine | Phase 3 | MDS |
| Pegylated Liposomal Doxorubicin Hydrochloride (PLD) | Phase 2 | High-grade Serous Ovarian Cancer |
| APR-246 | Phase 2 | Acute Myeloid Leukemia or Myelodysplastic Syndromes |
| ATRN-119 | Phase 2 | Advanced Solid Tumor |
| Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD) | Phase 2 | Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53 |
| APR-246 (eprenetapopt) + Pembrolizumab | Phase 2 | Bladder Cancer |
Price & technical context
3-month
-17.7%
6-month
-39.3%
12-month
-63.6%
52-wk range
$0.45–$1.45
vs 50-day MA
-27.7%
vs 200-day MA
-32.8%
Realized vol
93.9%
Max drawdown
-89.9%
Daily closes through 2026-10-27. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for APRE (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.